Measure of Acceptance of chRonic Visible sKin conditionS
Conditions: Acceptance of Visible Chronic Dermatological Disease; Disease Acceptance; Psychological Well-Being; Social Segregation Interventions: Behavioral: Questionnaire Sponsors: University Hospital, Tours; INSERM UMR 1246 SPHERE Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 27, 2023 Category: Research Source Type: clinical trials
Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe Atopic Dermatitis
Conditions: Atopic Dermatitis Interventions: Biological: OpSCF; Biological: Placebo; Biological: OpSCF (Open Label Extension) Sponsors: Opsidio, LLC; Innovaderm Research Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 26, 2023 Category: Research Source Type: clinical trials
Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent ® for Moderate to Severe Atopic Dermatitis
Conditions: Moderate to Severe Atopic Dermatitis Sponsors: Sanofi; Regeneron Pharmaceuticals Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 25, 2023 Category: Research Source Type: clinical trials
A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Dermatosis Papulosa Nigra (DPN)
Conditions: Dermatosis Papulosa Nigra Interventions: Drug: SM-020 gel 1.0% Sponsors: DermBiont, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 25, 2023 Category: Research Source Type: clinical trials
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial of Cardamom and Topical Roseomonas in Atopic Dermatitis
Conditions: Atopic Dermatitis; Eczema Interventions: Drug: Roseomonas mucosa (RSM2015)& Cardamom seeds; Drug: Placebo (sucrose) Sponsors: National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 24, 2023 Category: Research Source Type: clinical trials
Cardamom and Topical Roseomonas in Atopic Dermatitis
Conditions: Atopic Dermatitis; Eczema Interventions: Drug: Roseomonas mucosa (RSM2015) and Cardamom seeds; Drug: Placebo (sucrose) Sponsors: National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 24, 2023 Category: Research Source Type: clinical trials
Evaluate the Safety, Tolerability of BAT6026
Conditions: Dermatitis, Atopic Interventions: Drug: Monoclonal antibody BAT6026; Drug: sodium chloride injection Sponsors: Bio-Thera Solutions Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 23, 2023 Category: Research Source Type: clinical trials
A Phase II Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic Dermatitis
Conditions: Atopic Dermatitis Interventions: Drug: AK120 Sponsors: Akeso Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 20, 2023 Category: Research Source Type: clinical trials
Nearly 80% of Patients with Moderate-to-Severe Atopic Dermatitis Maintained Clear or Almost Clear Skin with Lilly's Lebrikizumab Monthly Maintenance Dosing at Two Years
INDIANAPOLIS, Oct. 20, 2023 /PRNewswire/ -- Patients with moderate-to-severe atopic dermatitis who continued treatment with investigational lebrikizumab for up to two years experienced sustained skin clearance, itch relief and reduced disease... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 20, 2023 Category: Pharmaceuticals Source Type: clinical trials
DMT310-009 Topical in the Treatment of Acne Vulgaris
Conditions: Acne Vulgaris Interventions: Drug: DMT310; Drug: Placebo Sponsors: Dermata Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2023 Category: Research Source Type: clinical trials
A Study of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis
Conditions: Atopic Dermatitis Interventions: Drug: LNK01001 Dose A; Drug: LNK01001 Dose B; Drug: placebo Sponsors: Lynk Pharmaceuticals Co., Ltd Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 17, 2023 Category: Research Source Type: clinical trials
LEO Pharma Presents Phase 3 Results of Delgocitinib Cream for Adults with Moderate to Severe Chronic Hand Eczema
BALLERUP, Denmark, October 13, 2023– LEO Pharma A/S, a global leader in medical dermatology, today presented results from the DELTA 2 trial at the 32nd European Academy of Dermatology and Venereology (EADV) Congress in Berlin. DELTA 2 is the... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 13, 2023 Category: Pharmaceuticals Source Type: clinical trials
A Phase 1 Study of LT-002-158 Intended for the Treatment of Skind Disorder in Healthy Adult Volunteers
Conditions: Hidradenitis Suppurativa; Atopic Dermatitis; Healthy Volunteer Interventions: Drug: LT-002-158/Placebo oral tablet(s) Sponsors: Shanghai Leadingtac Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 13, 2023 Category: Research Source Type: clinical trials
Triamcinolone Acetonide: Injections (Syringe and Needle) x Micro Injections (MMP Technique)
Conditions: Lichen Sclerosus of External Female Genital Organs Interventions: Procedure: Infiltration of triamcinolone acetonide (2mg/ml) through syringes and needles; Procedure: Infiltration of triamcinolone acetonide 40 mg/ml) through tattoo machines Sponsors: Clinica Dermatologica Arbache ltda Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 12, 2023 Category: Research Source Type: clinical trials
Comparison of Dermatoscopy X400 Interpreted by 6 Non-dermatologists and an Artificial Intelligence Software Skin Artificial Intelligence Versus Dermatoscopy x 20
Conditions: Genital Tumor; Pigmented Lesions Interventions: Other: Analysis of photos of pigmented tumours by the three groups Sponsors: Centre Hospitalier Universitaire de Saint Etienne Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 12, 2023 Category: Research Source Type: clinical trials
